Frutarom enters German market with red vine leaf extract

Frutarom penetrates the German vascular health market with its Vitis vinifera L., Red Vine Leaf Extract EFLA 945, following the latest European Patent Office (EPO) decision to revoke Böhringer Ingelheim’s patent EP 1 300 084 "composition for treatment of chronic venous insufficiencies (CVI) comprising of an extract of red vine leaves."

“On September 20, 2011, EPO’s final conclusion to revoke this patent opened new horizons for our Vitis vinifera L. aqueous extract,” says Raul Cortada, global VP of sales and marketing for Frutarom Health.

“The ingredient is scientifically backed by bibliographic studies and its standardization of three markers namely polyphenols, anthocyanins and trans-resveratrol.”

Varicose veins are a relatively common condition, and for many people they are a family trait.

Women are twice as likely as men to develop its symptoms.

In the US, nearly 10% of adult men and 20% of adult women suffer from the precursive “Heavy Legs” syndrome to some extent.

The company says EFLA 945 contains high, amounts of polyphenols and anthocyanins (which have a distinctive antioxidant effect) and trans-resveratrol to inhibit the platelet agglutination involved in heavy leg syndrome and varicose veins.

The ingredient is said to support vascular health via three mechanisms countering CVI resulting in vessel protection; promoting lipid metabolism; and reducing plaque formation for atherosclerosis.